Clinical performance of calcitonin and procalcitonin Elecsys
calcitonin
immunoassay
medullary thyroid carcinoma
procalcitonin
reflex test
Journal
Clinical chemistry and laboratory medicine
ISSN: 1437-4331
Titre abrégé: Clin Chem Lab Med
Pays: Germany
ID NLM: 9806306
Informations de publication
Date de publication:
26 03 2021
26 03 2021
Historique:
received:
21
09
2020
accepted:
13
10
2020
pubmed:
22
10
2020
medline:
5
1
2022
entrez:
21
10
2020
Statut:
epublish
Résumé
Medullary thyroid carcinoma (MTC) is caused by a malignant transformation in the parafollicular C-cells of the thyroid, where calcitonin (CT) is released. Nowadays, CT is the main tumor marker used in the diagnosis and follow-up of MTC patients. Nonetheless, procalcitonin (PCT) has recently been proposed as a useful complementary/alternative biomarker in MTC. Our aims were to investigate the diagnostic performance of CT and PCT and their combination in the differential diagnosis between active and inactive MTC and between MTC and non-MTC thyroid diseases, respectively. Serum samples were collected from 16 patients with active (i.e. primary tumour before surgery or post-surgical recurrent disease) and 23 with inactive (i.e. complete remission) MTC, 125 patients with non-MTC benign thyroid disease and 62 patients with non-MTC thyroid cancers, respectively. Elecsys Both CT and PCT median values in active MTC (94 pmol/L and 1.17 ng/mL, respectively) were significantly higher compared with inactive MTC (0.28 and 0.06) and either benign (0.37 and 0.06) or malignant (0.28 and 0.06) non-MTC. Undetectable PCT was found in five non-MTC patients with false positive CT results. Elecsys
Identifiants
pubmed: 33085633
doi: 10.1515/cclm-2020-1424
pii: /j/cclm.ahead-of-print/cclm-2020-1424/cclm-2020-1424.xml
doi:
Substances chimiques
Biomarkers, Tumor
0
Procalcitonin
0
Calcitonin
9007-12-9
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
743-747Informations de copyright
© 2020 Luca Giovanella et al., published by De Gruyter, Berlin/Boston.
Références
Trimboli, P, Giovanella, L, Crescenzi, A, Romanelli, F, Valabrega, S, Spriano, G, et al. Medullary thyroid cancer diagnosis: an appraisal. Head Neck 2014;36:1216–23. https://doi.org/10.1002/hed.23449.
Bae, YJ, Schaab, M, Kratzsch, J. Calcitonin as biomarker for the medullary thyroid carcinoma. Rec Res Canc Res 2015;2014:117–37. https://doi.org/10.1007/978-3-319-22542-5_5.
Frank-Raue, K, Schott, M, Raue, F. Recommendation for calcitonin screening in nodular goiter. Dtsch Med Wochenschr 2018;143:1065–69. https://doi.org/10.1055/a-0585-8097.
Trimboli, P, Giovanella, L. Serum calcitonin negative medullary thyroid carcinoma: a systematic review of the literature. Clin Chem Lab Med 2015;53:1507–14. https://doi.org/10.1515/cclm-2015-0058.
Austin, LA, Heath, H. Calcitonin: physiology and pathophysiology. N Engl J Med 1981;304:269–78. https://doi.org/10.1056/nejm198101293040505.
Cavalier, E, Carlisi, A, Chapelle, JP, Delanaye, P. Analytical quality of calcitonin determination and its effect on the adequacy of screening for medullary carcinoma of the thyroid. Clin Chem 2008;54:929–30. https://doi.org/10.1373/clinchem.2007.100636.
Giovanella, L, Imperiali, M, Ferrari, A, Palumbo, A, Lippa, L, Peretti, A, et al. Thyroid volume influences serum calcitonin levels in a thyroid-healthy population: results of a 3-assay, 519 subjects study. Clin Chem Lab Med 2012;50:895–900. https://doi.org/10.1515/cclm-2011-0920.
Machens, A, Ukkat, J, Hauptmann, S, Dralle, H. Abnormal carcinoembryonic antigen levels and medullary thyroid cancer progression. A multivariate analysis. Arch Surg 2007;142:289–93. https://doi.org/10.1001/archsurg.142.3.289.
van Veelen, W, de Groot, JWB, Acton, DS, Hofstra, RMW, Hoeppener, JWM, Links, TP, et al. Medullary thyroid carcinoma and biomarkers: past, present and future. J Intern Med 2009;266:126–40. https://doi.org/10.1111/j.1365-2796.2009.02106.x.
Wells, SAJr, Asa, SL, Dralle, H, Elisei, R, Evans, DB, Gagel, RF, et al. Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid 2015;25:567–610. https://doi.org/10.1089/thy.2014.0335.
Bihan, H, Becker, KL, Snider, RH, Nylen, E, Vittaz, L, Lauret, C, et al. Calcitonin precursor levels in human medullary thyroid carcinoma. Thyroid 2003;13:819–22. https://doi.org/10.1089/105072503768499716.
Algeciras-Schimnich, A, Preissner, CM, Theobald, JP, Finseth, MS, Grebe, SK. Procalcitonin: a marker for the diagnosis and follow-up of patients with medullary thyroid carcinoma. J Clin Endocrinol Metab 2009;94:861–8. https://doi.org/10.1210/jc.2008-1862.
Giovanella, L, Verburg, FA, Imperiali, M, Valabrega, S, Trimboli, P, Ceriani, L. Comparison of serum calcitonin and procalcitonin in detecting medullary thyroid carcinoma among patients with thyroid nodules. Clin Chem Lab Med 2013;51:1477–81. https://doi.org/10.1515/cclm-2012-0610.
Giovanella, L, Imperiali, M, Piccardo, A, Taborelli, M, Verburg, FA, D’Aurizio, F, et al. Procalcitonin measurement to screen medullary thyroid carcinoma: a prospective evaluation in a series of 2705 patients with thyroid nodules. Eur J Clin Invest 2018;48: e12934. https://doi.org/10.1111/eci.12934.
Machens, A, Lorenz, K, Dralle, H. Utility of serum procalcitonin for screening and risk stratification of medullary thyroid cancer. J Clin Endocrinol Metab 2014;99:2986–94. https://doi.org/10.1210/jc.2014-1278.
Trimboli, P, Giovanella, L. Procalcitonin as marker of recurrent medullary thyroid carcinoma: a systematic review and meta-analysis. Endocrinol Metab 2018;33:204–10. https://doi.org/10.3803/enm.2018.33.2.204.
Giovanella, L. Serum procalcitonin and calcitonin normal values before and after calcium gluconate infusion. Exp Clin Endocrinol Diabetes 2012;120:169–70. https://doi.org/10.1055/s-0031-1301290.
Kratzsch, J, Petzold, A, Raue, F, Reinhardt, W, Bröcker-Preuss, M, Görges, R, et al. Basal and stimulated calcitonin and procalcitonin by various assays in patients with and without medullary thyroid cancer. Clin Chem 2011;57:467–74. https://doi.org/10.1373/clinchem.2010.151688.
Giovanella, L, Giordani, I, Imperiali, M, Orlandi, F, Trimboli, P. Measuring procalcitonin to overcome heterophilic-antibody-induced spurious hypercalcitoninemia. Clin Chem Lab Med 2018;56:191–93. https://doi.org/10.1515/cclm-2017-0993.
Lim, SK, Guéchot, J, Vaubourdolle, M. Negative predictive value of procalcitonin in medullary thyroid carcinoma. Ann Biol Clin 2016;74:213–8. https://doi.org/10.1684/abc.2015.1115.
Schiettecatte, J, Strasser, O, Anckaert, H, Smitz, J. Performance evaluation of an automated electrochemiluminescent calcitonin (CT) immunoassay in diagnosis of medullary thyroid carcinoma. Clin Biochem 2016;49:929–31. https://doi.org/10.1016/j.clinbiochem.2016.05.006.
Kahaly, GJ, Algeciras-Schimnich, A, Davis, TE, Diana, T, Feldkamp, J, Karger, S, et al. United States and European Multicenter prospective study for the analytical performance and clinical validation of a novel sensitive fully automated immunoassay for calcitonin. Clin Chem 2017;63:1489–96. https://doi.org/10.1373/clinchem.2016.270009.
Conover, WJ. Practical nonparametric statistics, Hoboken, USA: 3rd ed. John Wiley & Sons; 1999.